Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24208929 | 0.85 | MAPT (0.62) | MAPTMEN1KMT2ASMN1; SMN2GAA | |
| SCHEMBL17010936 | 0.84 | PTGS1 (0.53) | SLC6A3MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL5949858 | 0.83 | SLC6A4 (0.54) | MAPTMEN1KMT2ASMN1; SMN2GAA | |
| SCHEMBL5950082 | 0.81 | MAPT (0.50) | MAPTMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL5445652 | 0.80 | PTGS1 (0.49) | MEN1KMT2ASMN1; SMN2POLBCA12 | |
| SCHEMBL14564435 | 0.80 | ALDH1A1 (0.49) | MAPTMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL5445969 | 0.78 | PTGS1 (0.48) | MAPTMEN1KMT2ASMN1; SMN2GAA | |
| SCHEMBL3321379 | 0.78 | KDM4E (0.56) | MAPTMEN1KMT2ASMN1; SMN2GAA | |
| SCHEMBL5800451 | 0.76 | ALDH1A1 (0.47) | MAPTMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL15775647 | 0.75 | SLC6A3 (0.53) | SLC6A3MEN1KMT2ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | SHIONOGI & CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | SHIONOGI & CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | SHIONOGI & CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| EP-1690538-A1 | ISOXAZOLE DERIVATIVE HAVING AGONISTIC ACTIVITY AGAINST PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | SHIONOGI & CO., LTD. (JP) | 2006-08-16 | — | — | EP | disclosed |
| US-20060148887-A1 | Chemical compounds | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2006-07-06 | — | — | US | disclosed |
| US-7034053-B2 | Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1366033-B1 | CHEMICAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2005-04-27 | — | — | EP | disclosed |
| US-20040106672-A1 | beta-adrenoceptor agonist for the prevention or treatment of obesity; Suitable compounds of formula (I) of the invention include:2-(3-{2R-[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]propylamino}phenyl)furan-3-carboxylic acid | B3AR THERAPEUTICS, INC. | 2004-06-03 | — | — | US | disclosed |
| CN-1487928-A | Compound (I) | — | 2004-04-07 | — | — | CN | disclosed |
| EP-1366033-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002060885-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106672-A1 | beta-adrenoceptor agonist for the prevention or treatment of obesity; Suitable compounds of formula (I) of the invention include:2-(3-{2R-[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]propylamino}phenyl)furan-3-carboxylic acid | ADRB3, ADRB1, ADRB2 | SLC6A3 436/4885MAPT 4140/4885MEN1 4297/4885 |
| US-20060148887-A1 | Chemical compounds | ADRB3, GPR119, ADRB1 | SLC6A3 427/4885MAPT 3892/4885MEN1 3551/4885 |
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | NR1H3, NR1H2, RXRA | SLC6A3 2080/4885MAPT 4429/4885MEN1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.